Literature DB >> 10833273

Characterization of human liver leukotriene B(4) omega-hydroxylase P450 (CYP4F2).

Y Kikuta1, E Kusunose, M Kusunose.   

Abstract

We previously reported the cloning of a human liver leukotriene B(4) (LTB(4)) omega-hydroxylase P450 designated CYP 4F2 [Kikuta et al. (1994) FEBS Lett. 348, 70-74]. However, the properties of CYP 4F2 remain poorly defined. The preparation solubilized using n-octyl-beta-D-glucopyranoside from microsomes of CYP 4F2-expressing yeast cells catalyzes v- hydroxylation of LTB(4), 6-trans-LTB(4), lipoxin A(4), 8-hydroxyeicosatetraenoate, 12-hydroxyeicosatetraenoate, and 12-hydroxystearate in the presence of rabbit liver NADPH-P450 reductase. In addition, the enzyme shows ethoxycoumarin O-deethylase and p-nitroanisole O-demethylase activities. The enzyme was purified to apparent electrophoretic homogeneity from yeast cells by sequential chromatography of solubilized microsomes through amino-n-hexyl-Sepharose 4B, DEAE-HPLC, and hydroxylapatite HPLC columns. The final preparation showed a specific content of 11.1 nmol of P450/mg of protein, with an apparent molecular mass of 56.3 kDa. CYP 4F2 was distinguished from the closely homologous CYP 4F3 (human neutrophil LTB(4) omega-hydroxylase) by its much higher K(m) for LTB(4), inability to omega-hydroxylate lipoxin B(4), and extreme instability.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10833273     DOI: 10.1093/oxfordjournals.jbchem.a022696

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  12 in total

Review 1.  Mechanisms for the prevention of vitamin E excess.

Authors:  Maret G Traber
Journal:  J Lipid Res       Date:  2013-03-15       Impact factor: 5.922

2.  Association of 1347 G/A cytochrome P450 4F2 (CYP4F2) gene variant with hypertension and stroke.

Authors:  Anjana Munshi; Vandana Sharma; Subhash Kaul; Amal Al-Hazzani; Ali A Alshatwi; Gowhar Shafi; Rajeshwar Koppula; Sai Babu Mallemoggala; A Jyothy
Journal:  Mol Biol Rep       Date:  2011-05-31       Impact factor: 2.316

3.  Expression of CYP4F2 in human liver and kidney: assessment using targeted peptide antibodies.

Authors:  Vandana Hirani; Anton Yarovoy; Anita Kozeska; Ronald P Magnusson; Jerome M Lasker
Journal:  Arch Biochem Biophys       Date:  2008-07-16       Impact factor: 4.013

4.  Association of a functional cytochrome P450 4F2 haplotype with urinary 20-HETE and hypertension.

Authors:  Hong Liu; Yanyan Zhao; Dong Nie; Jingpu Shi; Lingyu Fu; Yan Li; Dahai Yu; Jingyu Lu
Journal:  J Am Soc Nephrol       Date:  2008-01-30       Impact factor: 10.121

Review 5.  Cytochrome P450 ω-Hydroxylases in Inflammation and Cancer.

Authors:  Amanda L Johnson; Katheryne Z Edson; Rheem A Totah; Allan E Rettie
Journal:  Adv Pharmacol       Date:  2015-06-27

6.  Inhibition of oxidative metabolism of tocopherols with omega-N-heterocyclic derivatives of vitamin E.

Authors:  Stephan Ohnmacht; Phillip Nava; Ryan West; Robert Parker; Jeffrey Atkinson
Journal:  Bioorg Med Chem       Date:  2008-07-13       Impact factor: 3.641

Review 7.  Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets.

Authors:  Bei Wang; Lujin Wu; Jing Chen; Lingli Dong; Chen Chen; Zheng Wen; Jiong Hu; Ingrid Fleming; Dao Wen Wang
Journal:  Signal Transduct Target Ther       Date:  2021-02-26

8.  Hepatic overproduction of 13-HODE due to ALOX15 upregulation contributes to alcohol-induced liver injury in mice.

Authors:  Wenliang Zhang; Wei Zhong; Qian Sun; Xinguo Sun; Zhanxiang Zhou
Journal:  Sci Rep       Date:  2017-08-21       Impact factor: 4.379

9.  Computational Insight Into Vitamin K1 ω-Hydroxylation by Cytochrome P450 4F2.

Authors:  Junhao Li; Hongxiao Zhang; Guixia Liu; Yun Tang; Yaoquan Tu; Weihua Li
Journal:  Front Pharmacol       Date:  2018-09-25       Impact factor: 5.810

Review 10.  Molecular Functionality of Cytochrome P450 4 (CYP4) Genetic Polymorphisms and Their Clinical Implications.

Authors:  Yazun Bashir Jarrar; Su-Jun Lee
Journal:  Int J Mol Sci       Date:  2019-08-31       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.